Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 1218-1223

  Snydman, David R ^a,b   McDermott, Laura A ^b   Jacobus, Nilda V ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTOLOZANE; CEFTOLOZANE PLUS TAZOBACTAM; CLINDAMYCIN; CXA 201; ERTAPENEM; IMIPENEM; LINEZOLID; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANAEROBIC BACTERIUM; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTEROIDES; BACTEROIDES CACCAE; BACTEROIDES FRAGILIS; BACTEROIDES OVATUS; BACTEROIDES THETAIOTAOMICRON; CLOSTRIDIUM; CONTROLLED STUDY; FUSOBACTERIUM; GRAM POSITIVE COCCI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREVOTELLA; PRIORITY JOURNAL; PROPIONIBACTERIUM;

ANAEROBIOSIS; ANTI-BACTERIAL AGENTS; BACTEROIDES FRAGILIS; CEPHALOSPORINS; CLOSTRIDIUM; DRUG COMBINATIONS; FUSOBACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PREVOTELLA; PROPIONIBACTERIUM;

EID: 84893465570     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02253-13     Document Type: Article

References (10)

1. Bulik CC, Christensen H, Nicolau DM. 2010. In vitro potency of CXA-101, a novel cephalosporin against Pseudomonas aeruginosa displaying various resistance phenotypes, including multidrug resistance. Antimicrob. Agents Chemother. 54:557-559. http://dx.doi.org/10.1128/AAC.00912-09.
2. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217. http://dx.doi.org/10.1128/AAC.01104-09.
3. Sader HS, Rhomberg PR, Farell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55:2390-2394. http://dx.doi.org/10.1128/AAC.01737-10.
4. Sader HS, Flamm RK, Farell DJ, Jones RN. 2012. Activity of the novel antimicrobial ceftolozane/tazobactam (CXA-201) tested against contemporary clinical strains from European hospitals, abstr P1443. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), London, England.
5. Titelman EI, Karlsson M, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70:137-141. http://dx.doi.org/10.1016/j.diagmicrobio.2011.02.004.
6. Snydman DR, Jacobus NV, McDermott LA, R. Ruthazer R., Golan Y, Goldstein EJC, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL. 2007. National survey on the susceptibility of B. fragilis group: report and analysis of trends from 1997-2004 in the United States. Antimicrob. Agents Chemother. 51: 1649-1655. http://dx.doi.org/10.1128/AAC. 01435-06.
7. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJC, Harrell L, Jenkins SG, Newton D, Pierson C, Rihs J, Yu VL, Venezia R, Iannini P, Finegold SM, Gorbach SL. 2010. Lessons learned from the anaerobe survey: historical perspectives and review of the most recent data 2005-2007. Clin. Infect. Dis. 50(Suppl 1):S26-S33. http://dx.doi.org/10.1086/647940.
8. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJC, Harrell LJ, Jenkins SG, Newton D, Pierson C, Rosenblatt J, Venezia R, Gorbach SL, Queenan AM, Hecht DW. 2011. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006-2009. Anaerobe 17:147-151. http://dx.doi.org/10.1016/j.anaerobe.2011.05.014.
9. Clinical and Laboratory Standards Institute. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard, CLSI document M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Pfizer. 2012. Tygacil monograph: interpretative criteria for tygacil. Pfizer, New York, NY.